The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

Condition:   Nonalcoholic Fatty Liver Disease Interventions:   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One;   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two;   Drug: Placebo - Study Part One;   Drug: Placebo - Study Part Two Sponsor:   ChemomAb Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials